Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2012 Sep;44(3):98-103.

History and use of del Nido cardioplegia solution at Boston Children's Hospital

Gregory S Matte, Pedro J del Nido
Editorial

History and use of del Nido cardioplegia solution at Boston Children's Hospital

Gregory S Matte et al. J Extra Corpor Technol. 2012 Sep.

Erratum in

  • J Extra Corpor Technol. 2013 Dec;45(4):262

Abstract

Cardioplegia is an integral and essential method of myocardial protection for patients of all ages requiring cardiac surgery in which the heart must be stopped. Numerous cardioplegia solutions and delivery methods have been developed. The del Nido cardioplegia solution has been in use for 18 years at Boston Children's Hospital. This is a unique four parts crystalloid to one part whole blood formulation that is generally used in a single-dose fashion. Although the formulation was originally developed for use in pediatric and infant patients, its use for adult cardiac surgery has been expanding. National and international inquiries to our institution regarding this cardioplegia have been increasing over the last 2 years. We present the developmental history, supporting theory, and current protocol for use of what is now referred to as del Nido cardioplegia.

PubMed Disclaimer

Conflict of interest statement

The senior author has stated that authors have reported no material, financial, or other relationship with any healthcare-related business or other entity whose products or services are discussed in this paper.

The authors have published an original article with the same title and subject matter: Mattes GS and del Nido PJ. Indian Journal of Extracorporeal Technology 2012;22:9–12.

Figures

Figure 1.
Figure 1.
(A) Cardioplegia bag connection line with an integral .2-μm crystalloid filter. (B) Cardioplegia reservoir. (C) Pump loop. (D) Cooling coil. (E) Temperature monitoring site. (F) Pressure monitoring site. (G) Bubble trap with an integral 270-μm filter. (H) Sterile field table lines shown connected to circuit.
Figure 2.
Figure 2.
(A) Cardioplegia bag with crystalloid component as provided by pharmacy. (B) Cardioplegia reservoir bag where the 4:1 (crystalloid: blood) components are mixed and recirculated. (C) Stopcock, line, and syringe used to inject bypass circuit blood into the cardioplegia circuit. (D) Cardioplegia roller head.
See this image and copyright information in PMC

References

    1. Patent 5,407,793. 1995. U.S. Patent and Trademark Office; Alexandria, VA.
    1. Allen BS.. Pediatric myocardial protection: Where do we stand? J Thorac Cardiovasc Surg. 2004;128:11–13. - PubMed
    1. Bilfinger TV, Moeller JT, Kurusz M, Grimson RC, Anagnostopoulos CE.. Pediatric myocardial protection in the United States: A survey of current clinical practice. Thorac Cardiovasc Surg. 1992;40:214–218. - PubMed
    1. Hiramatsu T, Zund G, Schermerhorn ML, Shinoka T, Minura T, Mayer JE Jr.. Age differences in effects of hypothermic ischemia on endothelial and ventricular function. Ann Thorac Surg. 1995;60:S501–S504. - PubMed
    1. Bove EL, Stammers AH.. Recovery of left ventricular function after hypothermic ischemia: Age-related differences in the isolated working rabbit heart. J Thorac Cardiovasc Surg. 1986;91:115–122. - PubMed

Substances

LinkOut - more resources